Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease.
Saved in:
| Title: | Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease. |
|---|---|
| Authors: | Tseng HF; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.; Department of Health System, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA., Sy LS; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Rayens E; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Ackerson BK; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Ku JH; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Wu J; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Luo Y; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Cheng Y; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Patel AR; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Solano Z; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., De Jesus J; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Amundsen B; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Florea A; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Chmielewski-Yee E; Vaccines and Infectious Disease Epidemiology, GSK, Rockville, MD, USA., Oraichi D; Real World Biostatistics, GSK, Rockville, MD, USA., Seifert H; Global Safety, GSK, Rockville, MD, USA., Yun H; Vaccines and Infectious Disease Epidemiology, GSK, Rockville, MD, USA., Qian L; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA. |
| Source: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2576981. Date of Electronic Publication: 2025 Dec 08. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
